Urine Cytology and Utility in Bladder Recurrence
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||Urine Cytology and Utility in Bladder Recurrence|
- Review bladder cancer patients and form a database in regards to urine cytology. [ Time Frame: 1 month ] [ Designated as safety issue: No ]
|Study Start Date:||September 2009|
|Study Completion Date:||September 2010|
|Primary Completion Date:||September 2010 (Final data collection date for primary outcome measure)|
Bladder cancer patients
Bladder cancer patients from one Beaumont Urologist.
In 2008 there was an estimated 68,810 new cases of bladder cancer, and 14,100 deaths. On the list of morbidity due to cancer, bladder cancer ranks number nine, yet is number one in dollars spent per cancer diagnosis and treatment.
Guidelines include cystoscopy and cytology/urine study every three months for the first 2 years and then every 6 months for the next 2 years, with the cycle being reset with every recurrence.
Urine cytology currently considered the gold standard for urine tests has many pros and cons. The points that keep it in use include: its high specificity, the ability to detect upper tract occurrence, and the ability to monitor the small population of those with bladder cancer whose disease becomes more aggressive. Opponents to cytology refer to the fact that is has low sensitivity that it is fairly subjective and that newer markers in comparison are improved.
There are multiple journal article which document the performance of cytology and the newer markers, the new markers versus cytology and then the performance of cytology in tandem with these new markers. The bottom line that is often overlooked is that cytology is expensive and each of the newer markers are at least as expensive as cytology. With the fact that a person who is diagnosed with non invasive bladder cancer can have up to 13 urine cytology's in 5 years without any recurrence we believe newer rational recommendations need to be made in regards to urine studies and bladder cancer follow up.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00971256
|Principal Investigator:||Joseph Mashni, MD||Beaumont Hospitals|